Abstract 4754
Background
Breast cancer is the second leading cause of cancer deaths among women. Most women with breast cancer undergo surgery and chemotherapy and/or radiotherapy. These treatments trigger various side effects, for example, shoulder immobility, numbness or tightness, and lymphedema of the arm. Exercise-induced adaptations and better muscular performance may attenuate mentioned symptoms and side effects. The aim of this research is to determine whether there is correlation between physical exercise and the relief of symptoms predominating during radiotherapy.
Methods
Study was designed as a longitudinal sudy. The participants were female patients hospitalized at Department for Oncology at Clinical Hospital Centre Osijek, with diagnosed breast cancer, who were treated with radiotherapy after mastectomy. Research was conducted with an anonymous questionnaire, designed for the purpose of this study.
Results
There were total of 36 respondents. There was correlation between feeling of worry about the course of the disease in the beginning and the end of treatment with opinion that targeted exercises will reduce the worry (Spearman’s rho 0,630, P < 0,001). Also, there was correlation between with opinion that targeted exercises will reduce the anger and assessment that exercises reduced that feeling (Spearman’s rho 0,625, P < 0,001). After the treatment, most of the respondents evaluated the benefit from exercise in reducing pain, anger, fear and worry with 4 on a scale from 1 do 5, and they evaluated the feeling that exercises helped them with grade 5 on a scale from 1 do 5. The majority of respondents expressed that they will continue to exercise at home.
Conclusions
In general, respondents had good attitudes toward physical activity. Most of them exercise few times weekly and they think that exercise is useful. They strongly agreed that they would recommend the exercise to other patients who are suffering from this disease, that they feel that exercises helped them and that their attitude about the importance of exercise changed in a positive direction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract